Our study predicts CHRM1 is a predicted candidate gene and novel therapeutic target for T2D, suggesting that the drug Pirenzepine may be repositioned as a novel therapeutic for T2D. This evidence concerns the gene CHRM1 and type 2 diabetes mellitus.